CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-10 | Ciechanover Isaac E. Chief Executive Officer | Sale | −4,500 | $19.64 | $88K | 384,278 |
| 2018-01-10 | Ciechanover Isaac E. Chief Executive Officer | Sale | −4,100 | $20.38 | $84K | 380,178 |
| 2017-12-29 | MCGRATH JOHN EVP & Chief Financial Officer | Sale | −32,000 | $20.00 | $640K | 96,654 |
| 2017-12-29 | Ciechanover Isaac E. Chief Executive Officer | Sale | −14,400 | $18.24 | $263K | 394,378 |
| 2017-12-29 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,900 | $19.04 | $55K | 391,478 |
| 2017-12-29 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,700 | $20.28 | $55K | 388,778 |
| 2017-12-28 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $15.15 | $33K | 408,778 |
| 2017-12-13 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.73 | $32K | 410,978 |
| 2017-12-12 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.56 | $32K | 413,178 |
| 2017-11-30 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.40 | $32K | 415,378 |
| 2017-11-29 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.09 | $31K | 417,578 |
| 2017-11-17 | Soffer Gad EVP & Chief Strategy Officer | Sale | −7,000 | $15.00 | $105K | 256,236 |
| 2017-11-16 | Clark Mitchall G. EVP & Chief R & QA Officer | Sale | −3,290 | $14.20 | $47K | 163,052 |
| 2017-11-16 | Gallagher Carol Giltner Director | Sale | −1,184 | $14.20 | $17K | 109,738 |
| 2017-11-15 | Soffer Gad EVP & Chief Strategy Officer | Option exercise | +4,146 | 263,236 | ||
| 2017-11-15 | Soffer Gad EVP & Chief Strategy Officer | Option exercise · Restricted Stock Units | −4,146 | 2,764 | ||
| 2017-11-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise | +829 | 344,134 | ||
| 2017-11-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −1,604 | $13.36 | $21K | 342,530 |
| 2017-11-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise · Restricted Stock Units | −829 | 553 | ||
| 2017-11-15 | Ciechanover Isaac E. Chief Executive Officer | Option exercise | +5,908 | 743,675 |
Page 39 of 44 · 867 trades